Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YCJ-01 full-spectrum cannabis extract for refractory epilepsy in tuberous sclerosis complex
2022-000490-13Phase 3Active
- Sponsor
- Oils4Cure
- Start
- Mar 2022
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of YCJ-01 in Tuberous sclerosis complex-associated refractory epilepsy (TSC-RE) (2 arms), sponsored by Oils4Cure. Started Mar 2022; status: active.
02
Drugs
YCJ-01
03
Conditions
Tuberous sclerosis complex-associated refractory epilepsy (TSC-RE)
Beyond the preview
Go deeper on 2022-000490-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000490-13.